Last reviewed · How we verify
Slow dose preemptive Atropine
Slow dose preemptive atropine blocks muscarinic acetylcholine receptors to prevent cholinergic toxicity and organophosphate poisoning effects.
Slow dose preemptive atropine blocks muscarinic acetylcholine receptors to prevent cholinergic toxicity and organophosphate poisoning effects. Used for Preemptive treatment for organophosphate or nerve agent exposure, Prevention of cholinergic crisis in high-risk occupational settings.
At a glance
| Generic name | Slow dose preemptive Atropine |
|---|---|
| Also known as | Atropine |
| Sponsor | Abant Izzet Baysal University |
| Drug class | Anticholinergic agent / Muscarinic antagonist |
| Target | Muscarinic acetylcholine receptors (M1-M5) |
| Modality | Small molecule |
| Therapeutic area | Toxicology / Emergency Medicine |
| Phase | FDA-approved |
Mechanism of action
Atropine is an anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors throughout the central and peripheral nervous systems. When administered preemptively at low doses, it prevents the excessive cholinergic stimulation that occurs during organophosphate or nerve agent exposure, thereby blocking muscarinic symptoms such as excessive salivation, bronchospasm, and bradycardia.
Approved indications
- Preemptive treatment for organophosphate or nerve agent exposure
- Prevention of cholinergic crisis in high-risk occupational settings
Common side effects
- Dry mouth
- Blurred vision
- Tachycardia
- Urinary retention
- Mydriasis (pupil dilation)
Key clinical trials
- The Effect of Low-dose Atropine on Sympathetic Blockade in Spinal Cesarean Section Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Slow dose preemptive Atropine CI brief — competitive landscape report
- Slow dose preemptive Atropine updates RSS · CI watch RSS
- Abant Izzet Baysal University portfolio CI